◀ Back to PARP1
JUN — PARP1
Text-mined interactions from Literome
Andreone et al., J Immunol 2003
:
Poly(ADP-ribose) polymerase-1 regulates activation of
activator protein-1 in murine fibroblasts
Martin-Oliva et al., Cancer Res 2006
(Cell Transformation, Neoplastic...) :
Inhibition of
PARP also
affected activator protein-1 (AP-1) activation but not nuclear factor-kappaB (NF-kappaB)
García et al., Ann Rheum Dis 2008
(Arthritis, Rheumatoid) :
PARP inhibition reduced TNF induced JNK phosphorylation and
AP-1 and NF kappaB binding activities were partially
impaired by treatment with PARP inhibitors or by PARP-1 knockdown
Mathieu et al., Oncogene 2008
(Leukemia, Promyelocytic, Acute...) :
Using specific PARP-1 inhibitors and siRNAs, we show that
PARP-1 is
essential for the synergistic apoptotic effect and
c-Jun N-terminal kinase 1 ( JNK1 ) activation triggered by the ATRA/TNFalpha combination
Pacurari et al., Environ Health Perspect 2008
(Neoplasms, Mesothelial) :
In the present study, we exposed mesothelial cells to SWCNTs and investigated reactive oxygen species ( ROS ) generation, cell viability, DNA damage, histone H2AX phosphorylation, activation of
poly(ADP-ribose) polymerase 1 ( PARP-1 ), stimulation of extracellular signal regulated kinase ( ERKs ), Jun N-terminal kinases (JNKs), protein p38, and
activation of
activator protein-1 (AP-1) , nuclear factor kappaB (NF-kappaB), and protein serine-threonine kinase ( Akt )
Li et al., Neurourol Urodyn 2010
(Diabetes Complications...) :
The aim of this study was to investigate whether the activation of
PARP and subsequent
activation of
c-Jun N-terminal kinase (JNK) and the mitochondrial apoptotic pathway are involved in the development of diabetic cystopathy